Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

gedatolisib (PF-05212384)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Celcuity, Pfizer

Drug class:

mTOR inhibitor, PI3K inhibitor, AKT inhibitor

Related drugs:

‹

everolimus (138)

temsirolimus (37)

GSK2126458 (17)

PF-04691502 (6)

niclosamide (1)

rapamycin topical (0)

ridaforolimus (0)

encapsulated rapamycin (0)

enzastaurin (3)

BAY 1082439 (1)

capivasertib (37)

pexidartinib (6)

dordaviprone (5)

antroquinonol (0)

›

HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	PF-05212384 Sensitive: B - Late Trials PF-05212384 Sensitive : B	PF-05212384 Sensitive: B - Late Trials PF-05212384 Sensitive : B
FGF19 amplification + ER positive	HER2 Negative Breast Cancer	FGF19 amplification + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
EGFR mutation + ER positive	HER2 Negative Breast Cancer	EGFR mutation + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
FGF3 amplification + ER positive	HER2 Negative Breast Cancer	FGF3 amplification + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
FGF4 amplification + ER positive	HER2 Negative Breast Cancer	FGF4 amplification + ER positive	HER2 Negative Breast Cancer	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3	palbociclib + PF-05212384 Sensitive: C3 – Early Trials palbociclib + PF-05212384 Sensitive : C3
PIK3CA E542Q	HER2 Positive Breast Cancer	PIK3CA E542Q	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA amplification	HER2 Positive Breast Cancer	PIK3CA amplification	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA N345K	HER2 Positive Breast Cancer	PIK3CA N345K	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA E453K	HER2 Positive Breast Cancer	PIK3CA E453K	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA H1047R	HER2 Positive Breast Cancer	PIK3CA H1047R	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3
PIK3CA E542K	HER2 Positive Breast Cancer	PIK3CA E542K	HER2 Positive Breast Cancer	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3	PF-05212384 + trastuzumab-pkrb Sensitive: C3 – Early Trials PF-05212384 + trastuzumab-pkrb Sensitive : C3